Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Net Income
Bottom-line profit after all expenses, interest, and taxes.
Utah Medical Products, Inc.NASDAQ: UTMD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $2.6M fell 14.4% year over year, ahead of the -16.3% change in trailing-twelve-month net income. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at -11.8% a year.
Context
- Net income amounted to 29.3% of revenue in FY2025, down 4.6 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -14.4% holds above the trailing-twelve-month pace of -16.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Net Income history
USD · from the income statement
- Latest · FY2025
- 11.29M USD
- Year-over-year change
- -18.7%
- 4-year CAGR
- -6.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.29M | -18.7% |
| FY2024 | 2024-12-31 | 13.87M | -16.6% |
| FY2023 | 2023-12-31 | 16.64M | +1.0% |
| FY2022 | 2022-12-31 | 16.47M | +11.4% |
| FY2021 | 2021-12-31 | 14.79M | — |
Net Income vs competitors
How UTMD compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.3% is the 6th highest of 11, against a peer median of -18.6%.
- Net income amounts to 28.9% of revenue for UTMD, versus a peer median of 64.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.33M USD | +292.3% | — | 20.1% | |
| LTM Mar 2026 | $10.85M USD | -16.3% | -11.8% | 28.9% | |
| LTM Mar 2026 | $7.91M USD | +148.0% | +616.7% | 5.6% | |
| LTM Mar 2026 | -$2.28M USD | +57.0% | — | 5.3% | |
| LTM Mar 2026 | -$37.11M USD | +23.5% | — | 24.5% | |
| LTM Mar 2026 | -$39.2M USD | -21.3% | — | 207.7% | |
| LTM Mar 2026 | -$71.04M USD | -47.6% | — | 62.5% | |
| LTM Mar 2026 | -$75.07M USD | -134.9% | — | 66.4% | |
| LTM Mar 2026 | -€86.12M EUR | -23.5% | — | 527.8% | |
| LTM Mar 2026 | -$111.13M USD | -30.5% | — | 17982.7% | |
| LTM Mar 2026 | -$151.66M USD | -15.8% | — | 323.5% | |
| Peer median (excluding UTMD) | — | -18.6% | +616.7% | 64.4% | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.05M | 52.28M | 50.22M | 40.9M | 38.52M |
| Cost of Revenue | 18.14M | 20.09M | 20.19M | 16.76M | 18.65M |
| Gross Profit | 30.92M | 32.2M | 30.04M | 24.14M | 19.88M |
| Gross Margin | 63.0% | 61.6% | 59.8% | 59.0% | 51.6% |
| Research & Development | 526K | 493K | 560K | 813K | 668K |
| Selling, General & Admin | 11.51M | 11.91M | 12.7M | 5.57M | 7.81M |
| Operating Expenses | 12.04M | 12.41M | 13.26M | 10.55M | 8.47M |
| Depreciation & Amortization | 7.28M | 7.08M | 6.37M | 2.77M | 2.95M |
| EBITDA | 26.35M | 27.74M | 24.75M | 19.57M | 17.06M |
| EBITDA Margin | 53.7% | 53.1% | 49.3% | 47.9% | 44.3% |
| Operating Income | 18.88M | 19.79M | 16.78M | 13.59M | 11.4M |
| Operating Margin | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Interest Income | 166K | 661K | 0 | 3.37M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 181K | 869K | 3.31M | 3.21M | 2.71M |
| Income Before Tax | 19.06M | 20.66M | 20.09M | 16.8M | 14.11M |
| Pre-Tax Margin | 38.9% | 39.5% | 40.0% | 41.1% | 36.6% |
| Income Tax Expense | 4.27M | 4.19M | 3.45M | 2.93M | 2.82M |
| Net Income | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
| Net Margin | 30.1% | 31.5% | 33.1% | 33.9% | 29.3% |
| EPS (Basic) | 4.05 | 4.53 | 4.57 | 3.96 | 3.41 |
| EPS (Diluted) | 4.04 | 4.52 | 4.57 | 3.96 | 3.48 |
| Weighted Avg Shares | 3.65M | 3.64M | 3.64M | 3.5M | 3.31M |
| Weighted Avg Shares (Diluted) | 3.66M | 3.64M | 3.64M | 3.5M | 3.24M |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.